News Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Delayed Toronto S.E. Other stock markets 09:30:00 2024-04-23 am EDT			5-day change	1st Jan Change
0.475 ^CAD	-1.04%		-6.86%	+10.47%

Mar. 27	Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 27	Satellos Bioscience Announces FY 2023 Results	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 08	BU
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Satellos Bioscience: Q4 Earnings Snapshot	Mar. 27	AQ
Satellos Bioscience Announces FY 2023 Results	Mar. 27	MT
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights	Mar. 27	BU
Satellos to Present at Upcoming Virtual Investor Conferences in March and April	Mar. 14	BU
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024	Mar. 05	BU
Satellos Presented "Positive" Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	Mar. 04	MT
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	Mar. 04	BU
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	Mar. 04	CI
Satellos Recognized as a Top 50 TSX Venture Exchange Company	Feb. 21	BU
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Feb. 20	BU
Satellos Bioscience Inc. Brief: Says Will commence trading on the Toronto Stock Exchange as of the opening of trading tomorrow	Feb. 14	MT
Satellos to Commence Trading on the Toronto Stock Exchange	Feb. 14	BU
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	Feb. 13	BU
Satellos Bioscience Inc. Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	Feb. 13	CI
Satellos Announces Management Team Update	Jan. 24	AQ
Satellos Bioscience Inc. Brief: Shares Jumped 13.4% on Monday; Co Recently Received Conditional Approval to Graduate to the Toronto Stock Exchange	Jan. 23	MT
Satellos Bioscience Inc. Brief: Announced Earlier Tuesday Management Team Update; Alan K. Jacobs, Chief Medical Officer Has Left to Pursue Other Opportunities; Jordan Dubow Engaged As Chief Medical Advisor	Jan. 23	MT
Satellos Bioscience Inc. Announces Executive Changes	Jan. 23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Summary

Filters